Nomura Asset Management CO LTD Vertex Pharmaceuticals Inc Transaction History

Nomura Asset Management CO LTD

  • $37.3 Billion
  • Q3 2025

A detailed history of Nomura Asset Management CO LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Nomura Asset Management CO LTD holds 112,333 shares of VRTX stock, worth $48.8 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
112,333
Previous 158,916 29.31%
Holding current value
$48.8 Million
Previous $70.7 Million 37.82%
% of portfolio
0.12%
Previous 0.2%

Shares

44 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025
SELL
$366.54 - $479.53 $17.1 Million - $22.3 Million
-46,583 Reduced 29.31%
112,333 $44 Million
Q2 2025

Aug 11, 2025
BUY
$421.16 - $509.5 $2.37 Million - $2.86 Million
5,621 Added 3.67%
158,916 $70.7 Million
Q1 2025

May 12, 2025
BUY
$402.49 - $513.76 $1.41 Million - $1.8 Million
3,496 Added 2.33%
153,295 $74.3 Million
Q4 2024

Feb 12, 2025
SELL
$396.64 - $516.74 $2.02 Million - $2.63 Million
-5,095 Reduced 3.29%
149,799 $60.3 Million
Q3 2024

Nov 15, 2024
BUY
$460.0 - $505.78 $3.14 Million - $3.45 Million
6,831 Added 4.61%
154,894 $72 Million
Q2 2024

Aug 14, 2024
BUY
$392.81 - $485.53 $6.56 Million - $8.11 Million
16,701 Added 12.71%
148,063 $69.4 Million
Q1 2024

May 13, 2024
SELL
$407.69 - $446.08 $7.89 Million - $8.63 Million
-19,353 Reduced 12.84%
131,362 $54.9 Million
Q4 2023

Feb 09, 2024
SELL
$343.0 - $410.68 $6.46 Million - $7.73 Million
-18,822 Reduced 11.1%
150,715 $61.3 Million
Q3 2023

Nov 03, 2023
BUY
$338.18 - $362.46 $1.3 Million - $1.4 Million
3,852 Added 2.32%
169,537 $59 Million
Q2 2023

Aug 14, 2023
SELL
$314.42 - $351.91 $5.98 Million - $6.69 Million
-19,008 Reduced 10.29%
165,685 $58.3 Million
Q1 2023

Jan 10, 2025
SELL
$283.23 - $323.1 $31.7 Million - $36.1 Million
-111,826 Reduced 37.71%
184,693 $58.2 Million
Q1 2023

May 11, 2023
SELL
$283.23 - $323.1 $31.7 Million - $36.1 Million
-111,826 Reduced 37.71%
184,693 $58.2 Million
Q4 2022

Jan 10, 2025
SELL
$285.76 - $321.48 $6.48 Million - $7.28 Million
-22,660 Reduced 7.1%
296,519 $85.6 Million
Q4 2022

Feb 14, 2023
SELL
$285.76 - $321.48 $6.48 Million - $7.28 Million
-22,660 Reduced 7.1%
296,519 $85.6 Million
Q3 2022

Jan 10, 2025
BUY
$273.83 - $305.53 $1.71 Million - $1.9 Million
6,227 Added 1.99%
319,179 $92.4 Million
Q3 2022

Nov 10, 2022
BUY
$273.83 - $305.53 $1.71 Million - $1.9 Million
6,227 Added 1.99%
319,179 $92.4 Million
Q2 2022

Jan 10, 2025
SELL
$234.96 - $292.55 $482,137 - $600,312
-2,052 Reduced 0.65%
312,952 $88.2 Million
Q2 2022

Aug 12, 2022
SELL
$234.96 - $292.55 $482,137 - $600,312
-2,052 Reduced 0.65%
312,952 $88.2 Million
Q1 2022

Jan 10, 2025
BUY
$221.42 - $260.97 $35.5 Million - $41.8 Million
160,110 Added 103.37%
315,004 $82.2 Million
Q1 2022

May 13, 2022
BUY
$221.42 - $260.97 $4.02 Million - $4.74 Million
18,150 Added 6.11%
315,004 $82.2 Million
Q4 2021

Jan 10, 2025
BUY
$177.01 - $223.45 $9.95 Million - $12.6 Million
56,197 Added 23.35%
296,854 $65.2 Million
Q4 2021

Feb 01, 2022
BUY
$177.01 - $223.45 $9.95 Million - $12.6 Million
56,197 Added 23.35%
296,854 $65.2 Million
Q3 2021

Jan 10, 2025
BUY
$181.39 - $202.99 $2.3 Million - $2.57 Million
12,681 Added 5.56%
240,657 $43.7 Million
Q3 2021

Nov 12, 2021
BUY
$181.39 - $202.99 $2.3 Million - $2.57 Million
12,681 Added 5.56%
240,657 $43.7 Million
Q2 2021

Jan 10, 2025
SELL
$187.49 - $221.1 $2.1 Million - $2.47 Million
-11,180 Reduced 4.67%
227,976 $46 Million
Q2 2021

Aug 06, 2021
SELL
$187.49 - $221.1 $2.1 Million - $2.47 Million
-11,180 Reduced 4.67%
227,976 $46 Million
Q1 2021

Jan 10, 2025
BUY
$207.02 - $241.31 $17.4 Million - $20.3 Million
84,262 Added 54.4%
239,156 $51.4 Million
Q1 2021

May 14, 2021
SELL
$207.02 - $241.31 $2.44 Million - $2.85 Million
-11,802 Reduced 4.7%
239,156 $51.4 Million
Q4 2020

Jan 10, 2025
BUY
$207.01 - $276.09 $19.9 Million - $26.5 Million
96,064 Added 62.02%
250,958 $59.3 Million
Q4 2020

Feb 12, 2021
BUY
$207.01 - $276.09 $2.26 Million - $3.01 Million
10,907 Added 4.54%
250,958 $59.3 Million
Q3 2020

Nov 12, 2020
BUY
$255.65 - $303.1 $14.6 Million - $17.3 Million
57,031 Added 31.16%
240,051 $65.3 Million
Q2 2020

Aug 13, 2020
BUY
$225.48 - $295.8 $2.73 Million - $3.58 Million
12,100 Added 7.08%
183,020 $53.1 Million
Q1 2020

May 14, 2020
BUY
$199.77 - $247.81 $22.6 Million - $28 Million
113,007 Added 195.13%
170,920 $40.7 Million
Q4 2019

Feb 13, 2020
SELL
$166.71 - $223.91 $592,820 - $796,223
-3,556 Reduced 5.79%
57,913 $12.7 Million
Q3 2019

Nov 13, 2019
BUY
$166.23 - $187.09 $587,789 - $661,550
3,536 Added 6.1%
61,469 $10.4 Million
Q2 2019

Aug 13, 2019
SELL
$164.61 - $190.37 $57,942 - $67,010
-352 Reduced 0.6%
57,933 $10.6 Million
Q1 2019

May 10, 2019
SELL
$163.73 - $194.7 $222,345 - $264,402
-1,358 Reduced 2.28%
58,285 $10.7 Million
Q4 2018

Feb 12, 2019
BUY
$151.91 - $192.21 $537,609 - $680,231
3,539 Added 6.31%
59,643 $9.88 Million
Q3 2018

Nov 07, 2018
BUY
$167.73 - $192.74 $120,094 - $138,001
716 Added 1.29%
56,104 $10.8 Million
Q2 2018

Aug 03, 2018
SELL
$145.72 - $169.96 $208,088 - $242,702
-1,428 Reduced 2.51%
55,388 $9.41 Million
Q1 2018

May 14, 2018
BUY
$151.6 - $177.13 $180,858 - $211,316
1,193 Added 2.14%
56,816 $9.26 Million
Q4 2017

Feb 14, 2018
BUY
$137.28 - $155.55 $3.27 Million - $3.71 Million
23,823 Added 74.92%
55,623 $8.34 Million
Q3 2017

Nov 13, 2017
SELL
$148.13 - $162.24 $3.17 Million - $3.47 Million
-21,390 Reduced 40.21%
31,800 $4.84 Million
Q2 2017

Aug 14, 2017
BUY
N/A
53,190
53,190 $6.86 Million

Others Institutions Holding VRTX

# of Institutions
1,786
Shares Held
231M
Call Options Held
1.83M
Put Options Held
1.21M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email